Product Code: DMKC0205920
This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2019, there were 187,040 incident and 714,260 prevalent cases of idiopathic pulmonary fibrosis (IPF) in adults aged 20 years and older worldwide, and forecasts that number to increase to 209,960 incident cases and 798,760 prevalent cases by 2028. Roche's Esbriet and Boehringer's Ofev are the only approved drugs for IPF. These drugs are administered via the oral route. The largest proportion of industry-sponsored drugs in active clinical development for IPF are in Phase II, with two drugs in Phase III.
- Therapies in development for IPF focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the oral route.
- High-impact upcoming events in the IPF space comprise topline Phase IIa trial results for PLN-74809, topline Phase II trial results for GLPG1205, and topline Phase III trial results for GLPG1690 and pamrevlumab.
- The overall likelihood of approval of a Phase I respiratory-other asset is 10.6%, and the average probability a drug advances from Phase III is 57.1%. Drugs, on average, take 11.2 years from Phase I to approval, compared to 9.5 years in the overall respiratory space.
- There have been 18 licensing and asset acquisition deals involving IPF drugs during 2015-20. The $5,375m global research and development collaboration agreement signed in 2019 between Gilead and Galapagos, pursuant to which Gilead gained access to Galapagos's drug discovery platform and current and future pipeline outside of Europe, was the largest deal.
- The distribution of clinical trials across Phase I-IV indicates that the majority of trials for IPF have been in the early and midphases of development, with 66% of trials in Phase I-II, and 34% in Phase III-IV.
- The US has a substantial lead in the number of IPF clinical trials globally. The UK leads the major European markets, while Israel has the top spot in Asia.
- Clinical trial activity in the IPF space is dominated by completed trials. Roche has the highest number of completed clinical trials for IPF, with 18 trials.
- Roche leads the industry sponsors with the highest overall number of clinical trials for IPF, followed by Boehringer Ingelheim.
TABLE OF CONTENTS
- Disease definition
- Patient segmentation
- Risk factors
- Pharmacologic treatment
- Non-pharmacologic treatments
RECENT EVENTS AND ANALYST OPINION
- GLPG1690 for IPF (July 14, 2019)
- INOpulse for IPF (January 7, 2019)
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
- BTD Makes Promedior's PRM-151 Stand Out In IPF Race; Will Bristol Bite?
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
- Roche Paying $390m Up Front For Fibrosis-Fighting Promedior
- Boehringer Further Buoys IPF Portfolio With Bridge's Autotaxin Inhibitor
- $5bn Galapagos Deal Won't Be Last For Gilead, Says O'Day
CLINICAL TRIAL LANDSCAPE
- Sponsors by status
- Sponsors by phase
- Recent events
LIST OF FIGURES
- Figure 1: Trends in incident cases of IPF, 2019-28
- Figure 2: Trends in prevalent cases of IPF, 2019-28
- Figure 3: Overview of pipeline drugs for IPF in the US
- Figure 4: Pipeline drugs for IPF, by company
- Figure 5: Pipeline drugs for IPF, by drug type
- Figure 6: Pipeline drugs for IPF, by classification
- Figure 7: INOpulse for IPF (January 7, 2019): Phase II/III - iNO-PF
- Figure 8: Key upcoming events in IPF
- Figure 9: Probability of success in the IPF pipeline
- Figure 10: Licensing and asset acquisition deals in IPF, 2015-20
- Figure 11: Parent patents in IPF
- Figure 12: Clinical trials in IPF
- Figure 13: Top 10 drugs for clinical trials in IPF
- Figure 14: Top 10 companies for clinical trials in IPF
- Figure 15: Trial locations in IPF
- Figure 16: IPF trials status
- Figure 17: IPF trials sponsors, by phase
LIST OF TABLES
- Table 1: Incident cases of IPF, 2019-28
- Table 2: Prevalent cases of IPF, 2019-28
- Table 3: Marketed drugs for IPF
- Table 4: Pipeline drugs for IPF in the US
- Table 5: GLPG1690 for IPF (July 14, 2019)
- Table 6: INOpulse for IPF (January 7, 2019)
- Table 7: Historical global sales, by drug ($m), 2014-18
- Table 8: Forecasted global sales, by drug ($m), 2020-24